ECCO 15 - ESMO 34 News 20-21 September, 2009
Prof Gordon McVie - ecancer Managing Editor
ECCO 15 - ESMO 34 News 20-21 September, 2009 ( Prof Gordon McVie - ecancer Managing Editor )
21 Sep 2009
ECCO 15 - ESMO 34 Chairs: Why join us in Berlin?
Why attend ECCO 15 - ESMO 34?
ECCO 15 - ESMO 34 Chairs: Why join us in Berlin? ( Why attend ECCO 15 - ESMO 34? )
22 Jul 2009
The Oncopolicy Roundtable: ECCO's President and special guests highlight key iss...
ECCO 15 - ESMO 34
The Oncopolicy Roundtable: ECCO's President and special guests highlight key issues ( ECCO 15 - ESMO 34 )
22 Jul 2009
Selecting appropriate first line lung cancer therapy
Dr Paul Bunn - University of Colorado, Denver, USA
Selecting appropriate first line lung cancer therapy ( Dr Paul Bunn - University of Colorado, Denver, USA )
8 Jul 2009
Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo
Dr Pierre Fouret - Institut Gustave Roussy, France
Lung cancer patients lacking MSH2 DNA repair protein fare better with chemo ( Dr Pierre Fouret - Institut Gustave Roussy, France )
3 Jul 2009
Targeting death receptors in chemo-resistant cancer cells
Prof Patrick Johnston - Queen's University Belfast, UK
Targeting death receptors in chemo-resistant cancer cells ( Prof Patrick Johnston - Queen's University Belfast, UK )
3 Jul 2009
ASCO: Pemetrexed extends survival as maintenance therapy
Dr. Chandra P. Belani - Penn State Cancer Institute, Hershey, Pennsylvania, USA
ASCO: Pemetrexed extends survival as maintenance therapy ( Dr. Chandra P. Belani - Penn State Cancer Institute, Hershey, Pennsylvania, USA )
18 Jun 2009
ASCO: Lung cancer screening by low-dose computed tomography results in high rate...
Dr. Jennifer M. Croswell - National Institutes of Health, Bethesda, Maryland, US...
ASCO: Lung cancer screening by low-dose computed tomography results in high rate of false positives ( Dr. Jennifer M. Croswell - National Institutes of Health, Bethesda, Maryland, USA )
18 Jun 2009
ASCO: Maintenance therapy for NSCLC
Dr. Vincent A. Miller - MD Memorial Sloan-Kettering Cancer Center, New York, US...
ASCO: Maintenance therapy for NSCLC ( Dr.  Vincent A. Miller - MD Memorial Sloan-Kettering Cancer Center, New York, USA )
18 Jun 2009
ASCO: Experimental targeted therapy improves progression-free survival for advan...
Dr Roy Herbst, M.D. Anderson Cancer Center, Houston, US
ASCO: Experimental targeted therapy improves progression-free survival for advanced NSCLC ( Dr Roy Herbst, M.D. Anderson Cancer Center, Houston, US )
17 Jun 2009
Oestrogen and progestin therapy increases NSCLC risk
Dr Rowan Chlebowski - Harbor-UCLA Medical Center, Los Angeles, US
Oestrogen and progestin therapy increases NSCLC risk ( Dr Rowan Chlebowski - Harbor-UCLA Medical Center, Los Angeles, US )
17 Jun 2009
AACR 2009: Common genetic variations and predisposition to cancer
Prof Bruce Ponder - Cancer Research UK, Cambridge Institute
AACR 2009: Common genetic variations and predisposition to cancer ( Prof Bruce Ponder - Cancer Research UK, Cambridge Institute )
14 May 2009